Treatment Action Group (TAG), the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), Society for Maternal-Fetal Medicine (SMFM) and HIV/AIDS Network Coordination Women’s HIV Research Collaborative (WHRC)
The U.S. Division of AIDS (DAIDS) and its prevention and International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) networks have a long history of including pregnant and lactating women in clinical trials and of developing research agendas that target long standing and new knowledge gaps necessary to meet the needs of this neglected population.
Treatment Action Group (TAG), the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), Society for Maternal-Fetal Medicine (SMFM) and HIV/AIDS Network Coordination Women’s HIV Research Collaborative (WHRC) invite you to join us for part II of our webinar series on the inclusion of pregnant and lactating women in research.
Join in Wednesday, March 14th from 10:00-11:30 AM ET to explore historic and ongoing efforts to facilitate the inclusion of pregnant women in tuberculosis (TB) and HIV research:
1) Historic perspective on HIV and TB research in pregnant women, Dr. Lynne Mofenson, Senior HIV Technical Advisor, EGPAF
2) An overview of ongoing and planned IMPAACT studies in pregnant women, Dr. Sharon Nachman, Stony Brook University, Chair of the IMPAACT network
3) Pregnant women in the DAIDS network re-competition, Carl Diffenbach, Director, Division of AIDS, U.S. National Institute of Allergy and Infectious Diseases
4) The role community advocates can play to advance a more inclusive research agenda, Liz Barr, AIDS Clinical Trials Group (ACTG) 5) Community Scientific Subcommittee co-chair, WHRC co-chair
5) Ensuring inclusion beyond IMPAACT: an update from the PRGLAC task force, Speaker TBC.